Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT

Scientific Reports
Jaideep B BharateHong-Yu Li

Abstract

FMS-like Tyrosine Kinase 3 (FLT3) is a clinically validated target for acute myeloid leukemia (AML). Inhibitors targeting FLT3 have been evaluated in clinical studies and have exhibited potential to treat FLT3-driven AML. A frequent, clinical limitation is FLT3 selectivity, as concomitant inhibition of FLT3 and c-KIT is thought to cause dose-limiting myelosuppression. Through a rational design approach, novel FLT3 inhibitors were synthesized employing a pyridine/pyrimidine warhead. The most potent compound identified from the studies is compound 13a, which exhibited an IC50 value of 13.9 ± 6.5 nM against the FLT3 kinase with high selectivity over c-KIT. Mechanism of action studies suggested that 13a is a Type-II kinase inhibitor, which was also supported through computer aided drug discovery (CADD) efforts. Cell-based assays identified that 13a was potent on a variety of FLT3-driven cell lines with clinical relevance. We report herein the discovery and therapeutic evaluation of 4,6-diamino pyrimidine-based Type-II FLT3 inhibitors, which can serve as a FLT3-selective scaffold for further clinical development.

References

Sep 13, 2003·Leukemia·M Levis, D Small
Dec 4, 2003·Expert Opinion on Investigational Drugs·Mark Levis, Donald Small
Nov 23, 2013·Blood·Amir T Fathi
Mar 14, 2014·Proceedings of the National Academy of Sciences of the United States of America·Catherine Choy SmithNeil P Shah
May 13, 2014·Bioorganic & Medicinal Chemistry Letters·Chun-Ho ParkGyoonhee Han
Sep 19, 2014·European Journal of Medicinal Chemistry·Brendan FrettHong-yu Li
Feb 21, 2016·European Journal of Pharmacology·Baratali MashkaniRenate Griffith
Feb 28, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Todd M CooperPatrick A Brown
May 18, 2016·ACS Medicinal Chemistry Letters·John M HatcherNathanael S Gray
Oct 23, 2016·Clinical Lymphoma, Myeloma & Leukemia·Mona HassaneinRiad El Fakih

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay
chip

Software Mentioned

GraphPad Prisim
AutoDock Tools
Discovery Studio
Studio
AutoDock Vina 33
Discovery
AutoDock Vina
SpectraMax
AutoDock

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.